Capricor Therapeutics (CAPR) BidaskScore is downgraded to Sold

Capricor Therapeutics, Inc.

The BidaskScore of Capricor Therapeutics Inc. CAPRCAPR shows that the shares of the company are now CAPRStrongly Bought Sold by investors.

The BidaskScore of the BiotechnologyBiotechnology shows that the sector is BiotechnologyStrongly Bought Strongly Sold since September 25.

Here are the BidAskScore of other related companies in the Biotechnology sector:

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.

Capricor Therapeutics, Inc.

Launched in 2016, the BidAskClubBidaskClub allows users to follow the evolution of the US equity market. BidaskClub provides a platform to create portfolios and be informed when a company´s or sector’s BidaskScore changes. BidaskClub is provided by LuxFinAdviceLuxFinAdvice.